Novo Nordisk A/S (NYSE:NVO) Trading 0.6% Higher

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was up 0.6% on Monday . The company traded as high as $132.68 and last traded at $132.66. Approximately 630,387 shares traded hands during trading, a decline of 87% from the average daily volume of 4,684,356 shares. The stock had previously closed at $131.89.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on NVO shares. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an "overweight" rating and a $120.00 target price on the stock. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an "outperform" rating and a $163.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $133.60.

Novo Nordisk A/S Trading Up 0.8 %

The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The company has a market cap of $596.53 billion, a P/E ratio of 45.84, a PEG ratio of 1.85 and a beta of 0.43. The firm's 50 day moving average is $128.10 and its two-hundred day moving average is $115.68.

Institutional Trading of Novo Nordisk A/S

Several institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC lifted its holdings in Novo Nordisk A/S by 100.0% in the third quarter. Allspring Global Investments Holdings LLC now owns 584 shares of the company's stock valued at $53,000 after buying an additional 292 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Novo Nordisk A/S by 229.4% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 11,236 shares of the company's stock valued at $1,022,000 after purchasing an additional 7,825 shares during the period. Banque Pictet & Cie SA raised its holdings in shares of Novo Nordisk A/S by 100.0% during the third quarter. Banque Pictet & Cie SA now owns 2,532 shares of the company's stock valued at $230,000 after purchasing an additional 1,266 shares during the period. Capital Investment Advisory Services LLC raised its holdings in shares of Novo Nordisk A/S by 25.3% during the third quarter. Capital Investment Advisory Services LLC now owns 2,285 shares of the company's stock valued at $208,000 after purchasing an additional 462 shares during the period. Finally, Coldstream Capital Management Inc. raised its holdings in shares of Novo Nordisk A/S by 99.0% during the third quarter. Coldstream Capital Management Inc. now owns 9,682 shares of the company's stock valued at $880,000 after purchasing an additional 4,816 shares during the period. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.